IGF1 and pulmonary arterial hypertension: Pulmonary Selectivity as a Central Challenge: The major obstacle in translating IGF-targeted therapies into PAH treatment is achieving pulmonary vascular selectivity while avoiding systemic metabolic and endocrine side effects.